VR Logo

Inhibikase Therapeutics Inc. (IKT) download report


Healthcare | Biotechnology & Pharma Research

Inhibikase Therapeutics Inc. (IKT) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain.

IPO Date: 23-Dec-2020

CEO, Pres & Director: Dr. Milton H. Werner Ph.D.

Chief Financial Officer: Mr. Joseph Frattaroli CPA

Listing: NASDAQ: IKT

Country: United States

Headquarters: Atlanta, GA

Website: https://www.inhibikase.com

Key Facts

Market cap: $22.64 Mln

Revenue (TTM): $1.74 Mln

Earnings (TTM): $-16.79 Mln

Cash: $36.61 Mln

Total Debt: $0.00 Mln

Insider's Holding: 21.32%

Liquidity: Low

52 Week range: $0.60 - 3.05

Shares outstanding: 25,227,100

6 Years Aggregate:

  • CFO: $-15.21 Mln
  • EBITDA: $-25.40 Mln
  • Net Profit: $-25.51 Mln

Stock Performance

Time Period Inhibikase Therapeutics (IKT) S&P BSE Sensex S&P Small-Cap 600
YTD-44.61-9.49-17.79
1 month7.13-2.87-2.72
3 months-43.06-8.59-12.17
1 Year-71.920.81-15.82
3 Years--10.397.14
5 Years--11.116.20
10 Years--12.0010.33
As on 24-Jun-2022
Year Inhibikase Therapeutics (IKT) S&P Small-Cap 600 S&P BSE Sensex
2021-78.7025.2721.99